Loughborough, England, Feb. 04, 2021 (GLOBE NEWSWIRE) — Nemaura Medical Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Firm”), a medical know-how firm centered on growing and commercializing non-invasive wearable diagnostic gadgets and supporting personalised way of life teaching packages, immediately declares the appointment of Thomas Mortensen as head of E.U. industrial operations and advertising.
“Tom is a crucial addition to our group, as he’ll head up our operations within the E.U for our deliberate direct to client product. His intensive expertise all through Europe will assist us decide one of the best ways to place our merchandise for country-specific audiences, and we look ahead to his management and steering as we ramp up our advertising actions,” stated Faz Chowdhury, Ph.D., Nemaura’s CEO.
Mr. Mortensen has spent greater than 25 years in commercialization and advertising for the medical system trade, principally related with heart problems and diabetes. Most just lately he served as head of selling at Roche Diabetes Care, the place he oversaw the digitalization of its group, making a extra environment friendly and profitable working group. As well as, he held management positions at Sunshine Coronary heart, Inc., Mivi Neuroscience, BG Medication, Inc., Circulite, Inc., and ev3, Inc. He holds a Bachelor of Science diploma from the Southern Denmark Enterprise College and an MBA from Odense College, Denmark.
“I look ahead to working with the Nemaura group to deliver what I imagine is an modern method to diabetes care, with a transparent historical past of medical proof to again it up. The combination of behavioral modification and a wearable, disposable system to intently monitor glucose tendencies is a model new and non-invasive methodology to actually influence the well-being of individuals with diabetes and pre-diabetes,” added Mr. Mortensen.
About Nemaura Medical, Inc.
Nemaura Medical Inc. is a medical know-how firm growing and commercializing non-invasive wearable diagnostic gadgets. The Firm is at the moment commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark accepted Class IIb medical system, is a non-invasive and versatile steady glucose monitor (CGM) offering actionable insights derived from actual time glucose measurements and every day glucose development information, which can assist individuals with diabetes and pre-diabetes to higher handle, reverse, and forestall the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Software) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose information processed utilizing synthetic intelligence and a digital healthcare subscription service and is predicted to be launched within the U.S. as a basic wellness product.
The Firm sits on the intersection of the worldwide Kind 2 diabetes market that’s anticipated to achieve practically $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight reduction and wellness functions that’s estimated to achieve $60 billion by 2023.
For extra data, please go to www.NemauraMedical.com.
Cautionary Assertion Concerning Ahead-Trying Statements:
The statements on this press launch that aren’t historic info might represent forward-looking statements which might be based mostly on present expectations and are topic to dangers and uncertainties that might trigger precise future outcomes to vary materially from these expressed or implied by such statements. These dangers and uncertainties embody, however will not be restricted to, the launch of proBEAT™ within the US, dangers associated to regulatory standing and the failure of future improvement and preliminary advertising efforts, Nemaura’s capability to safe extra industrial partnering preparations, dangers and uncertainties referring to Nemaura and its companions’ capability to develop, market and promote proBEAT™, the provision of considerable extra fairness or debt capital to assist its analysis, improvement and product commercialization actions, and the success of its analysis, improvement, regulatory approval, advertising and distribution plans and techniques, together with these plans and techniques associated to each proBEAT™ digital well being, and sugarBEAT®. There could be no assurance that the corporate will be capable of attain part of or any of the worldwide marketplace for CGM with its merchandise/providers. The FDA reserves the best to re-evaluate their choice that proBEAT™ qualifies as a basic wellness product ought to it change into conscious of any points equivalent to pores and skin irritation or different hostile occasions from the system, in addition to any misuse impacting affected person security, and every other motive because the FDA might even see match at its discretion to find out the product doesn’t match the definition of a basic wellness product. These and different dangers and uncertainties are recognized and described in additional element in Nemaura’s filings with the USA Securities and Change Fee, together with, with out limitation, its Annual Report on Type 10-Ok for essentially the most just lately accomplished fiscal 12 months, its Quarterly Studies on Type 10-Q, and its Present Studies on Type 8-Ok. Nemaura undertakes no obligation to publicly replace or revise any forward-looking statements.